AAIPHARMA SERVICES AND CAMBRIDGE MAJOR LABORATORIES ANNOUNCE THE APPOINTMENT OF MARCEL SCHREUDER GOEDHEIJT AS GENERAL MANAGER OF CAMBRIDGE MAJOR LABORATORIES – EUROPE
Weert, Netherlands. Sept. 30, 2014 /Businesswire/ AAIPharma Services Corp. (“AAIPharma”), a leading global provider of pharmaceutical analytical testing, product development and manufacturing services and Cambridge Major Laboratories, Inc. (“CML”), a global leader in pharmaceutical API development and manufacturing, announce the appointment of Marcel Schreuder Goedheijt, Ph.D. as General Manager, Cambridge Major Laboratories – Europe.
“Dr. Schreuder Goedheijt has excellent experience and leadership skills, and he is dedicated to providing the best service and capabilities in our industry,” said Stephan Kutzer, Chief Executive Officer.
Dr. Kutzer continued, “Dr. Schreuder Goedheijt assumed the role of site leader for the Cambridge Major Laboratories-Europe site in Weert, Netherlands, as part of a comprehensive succession plan that has been in process since Dr. Schreuder Goedheijt joined the CML organization last year. In this role, Marcel is responsible for directing the day to day business activities as a leading global service-based chemistry outsourcing partner to the pharmaceutical and biotechnology industries – producing pharmaceutical intermediates, API’s and other fine organic chemicals.”
Dr. Schreuder Goedheijt added, “I am very happy to be part of a leading, growing team at this exciting time and look forward to helping provide exemplary pharmaceutical manufacturing services.”
With over 15 years of experience in the chemical and pharmaceutical industries, Dr. Schreuder Goedheijt has held leadership positions at DSM Pharma Chemicals, MSD (Organon) and Diosynth. He holds a Ph.D. from Free University Amsterdam and a M.B.A. from Stichting Leergang Bedrijfskunde Arnhem, Netherlands.
About AAIPharma Services Corp. and Cambridge Major Laboratories, Inc.
AAIPharma Services Corp. and Cambridge Major Laboratories, Inc. have joined to form a world-class supplier of comprehensive pharmaceutical development and manufacturing services. With over 800 employees operating out of seven sites in the US and Europe, combined capabilities include API development and manufacturing, solid state chemistry, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (solid dose and parenteral), packaging, and stability services. The family of companies is in the portfolio of American Capital, Ltd. (NASDAQ: ACAS).
For more information on the companies, visit www.aaipharma.com and www.c-mlabs.com/.
SOURCE: AAIPharma